Level D· Scientific groundwork from lab and animal studiesNarrative ReviewEurope PMC

Functional genomics and assays of regulatory activity detect mechanisms at loci for lipid traits and coronary artery disease

Roman TS., Mohlke KL.

Narrative Review, published in Curr Opin Genet Dev (2018) — summary generated from the PubMed abstract.

Open my reading list
Level D· Scientific groundwork from lab and animal studiesEvidence level of this study

Evidence from laboratory and animal studies provides groundwork for understanding mechanisms and potential before human studies continue.

  • Level A · Stronger Clinical Evidence
  • Level B · Emerging clinical evidence with positive signals
  • Level C · Early human research exploring benefits
  • Level D · Scientific groundwork from lab and animal studies
  • Emerging · Emerging topic under active research
Read the A–D evidence level guide

This page is generated from the PubMed record. The Thai description is an automated summary of bibliographic fields and the abstract, not a full translation, and is not medical advice.

Study type
Narrative Review
Journal
Curr Opin Genet Dev (2018)
Reported sample size
—
Source database
Europe PMC
PMID
29471259
PMCID
PMC6089635
DOI
10.1016/j.gde.2018.02.004
Citations
6

Abstract (original English)

Many genome-wide association studies (GWAS) have identified signals located in non-coding regions, and an increasing number of functional genomics annotations of regulatory elements and assays of regulatory activity have been used to investigate mechanisms. Genome-wide datasets that characterize chromatin structure help detect potential regulatory elements. Assays to experimentally assess candidate variants include transcriptional reporter assays, and recently, massively parallel reporter assays (MPRAs). Additionally, the effect of candidate regulatory elements and variants on gene expression and function can be evaluated using genomic editing with the CRISPR-Cas9 technology. We highlight some recent studies that employed these strategies to identify variant effects and elucidate molecular and/or biological mechanisms at GWAS loci for lipid traits and coronary artery disease.

What this study does not prove

  • • This study does not prove SVF is an approved treatment or a replacement for standard care.
  • • This is a narrative review: it collects no new patient data and does not systematically appraise evidence quality.

Evidence level

Evidence from laboratory and animal studies provides groundwork for understanding mechanisms and potential before human studies continue.

How we grade evidence
HumansGenetic Predisposition to DiseaseLipidsGenomicsQuantitative Trait LociGenome, HumanCoronary Artery DiseaseGenome-Wide Association Study

Browse all related research

Filter the research library by this study's title keywords, author, or publication year.